• Biogen outlined new Alzheimer’s disease data disclosures planned for AAIC 2026 in London on July 12-15.
• Phase 2 CELIA results for diranersen in early Alzheimer’s were previously released as topline findings in May 2026.
• Initial clinical, biomarker, and safety findings from CELIA will be presented in a future AAIC session on July 14.
• Additional AAIC presentations will focus on lecanemab, including emerging evidence for subcutaneous dosing, at-home use, and real-world experience.
• Biogen also flagged three-year post-approval LEADER analyses, including maintenance dosing and patient pathway findings, for AAIC presentation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290659PRIMZONEFULLFEED9753777) on June 29, 2026, and is solely responsible for the information contained therein.